Ionis Pharmaceuticals Inc... (IONS)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 10:15 AM EDT Company Participants Brett Monia - Founder, CEO & Director Conference Call ...

Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.

Ionis Pharmaceuticals' stock jumped 35% on September 2, 2025, after positive late-stage clinical trial results for olezarsen, a therapy for severe hypertriglyceridemia (sHTG). Investor enthusiasm is a...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 2025 Wells Fargo...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Positive CORE and CORE2 Topline Results Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Sot...

Ionis Pharmaceuticals stock jumped 31% on Tuesday hitting a new 52-week high after breakthrough news that lit up investor interest and boosted confidence across the biotech sector.

Ionis Pharmaceuticals, Inc. IONS on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG).

Ionis Pharmaceuticals' shares surged on Tuesday before the bell after the drugmaker said its experimental treatment significantly reduced levels of blood fats called triglycerides and reduced pancreat...

mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...

Ionis Pharmaceuticals remains a Buy after Dawnzera's FDA approval, which strengthens its pipeline and revenue outlook despite a history of operating losses. Dawnzera's market opportunity in hereditary...